Prevalence and Prognosis of Cardiac Amiloidosis in Turkey (PAPCAT)

May 31, 2021 updated by: Turkish Society of Cardiology

Prevalence and Prognosis of Cardiac Amiloidosis in Turkey- Registry Study

Patients with left ventricular hypertrophy are further examined according to an algorithm to check if they have a cardiac amyloidosis

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

2087

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Ilkay Gucuk, MD
  • Phone Number: 902122211738
  • Email: tkd@tkd.org.tr

Study Locations

  • Turkey
      • Izmir, Turkey
        • Recruiting
        • Dokuz Eylul University Faculty of Medicine
        • Contact:
          • Ebru Ozpelit, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with left ventricular hypertrophy

Description

Inclusion Criteria:

  • Patients with left ventricular hypertrophy without left ventricular pressure or volume (IVS≥13mm)
  • Patients with left ventricular hypertrophy and hypertension or aortic stenosis without left ventricular pressure or volume (IVS>15mm)

Exclusion Criteria:

  • Patients with left ventricular pressure or volume except the ones with aortic stenosis and arterial hypertension
  • Patients with sigmoid septum and their hypertrophy limited in sigmoid area
  • Patients with highly probable sarcometric hypertrophy cardiomyopathy confirmed with LV morhpology and genetic testing

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiac Amyloidosis
Time Frame: Upon screening
Patients with left ventricular hypertrophy and Cardiac Amyloidosis
Upon screening

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Turkish Society of Cardiology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 18, 2020

Primary Completion (ANTICIPATED)

December 31, 2025

Study Completion (ANTICIPATED)

December 31, 2025

Study Registration Dates

First Submitted

May 31, 2021

First Submitted That Met QC Criteria

May 31, 2021

First Posted (ACTUAL)

June 7, 2021

Study Record Updates

Last Update Posted (ACTUAL)

June 7, 2021

Last Update Submitted That Met QC Criteria

May 31, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PAPCAT

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiac Amyloidosis

Clinical Trials on Algorithm

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe